Xeris Pharmaceuticals received a notice of allowance from the U.S. Patent and Trademark Office for a new patent covering KEVEYIS, its treatment for primary periodic paralysis. The patent, titled "Compositions and Methods of Use," is expected to provide intellectual property protection for the drug through 2039.

The USPTO notice indicates the patent application meets patentability requirements and will issue as a U.S. patent following standard administrative steps. Xeris plans to submit the patent to the FDA for listing in the Orange Book, the agency's publication of approved drug products with therapeutic equivalence evaluations.

KEVEYIS (dichlorphenamide) is an FDA-approved treatment for primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. Primary periodic paralysis is a rare genetic condition affecting muscles and causing episodes of muscle weakness and temporary paralysis.

"KEVEYIS is the first FDA-approved therapy for primary periodic paralysis, a rare and debilitating condition, and this Notice of Allowance reflects our long-standing commitment to this highly underserved patient community who depend on it," said John Shannon, CEO of Xeris.

Xeris Pharmaceuticals operates as a wholly owned subsidiary of Biopharma Holdings, Inc. (NASDAQ: XERS). The company has three commercially available products: RECORLEV for endogenous Cushing's syndrome, GVOKE for severe hypoglycemia, and KEVEYIS for primary periodic paralysis.

The information is based on a company press release statement.